The levels of immune cell infiltration and PD-L1 expression in TNBC are significantly higher than in other subtypes of breast cancer, indicating that PD-1/PD-L1 inhibitors may have potential therapeutic value in TNBC. The gene discussed is PDCD1; the disease is breast cancer.